GSK has reached an agreement in principle with Novavax and the UK Government Vaccines Taskforce to support manufacturing of up to 60 million doses of Novavax’ COVID-19 vaccine candidate (NVX-CoV2373) for use in the UK. GSK will provide ‘fill and finish’ manufacturing capacity at its Barnard Castle facility in the North East of England beginning as early as May 2021, with a rapid technology transfer between the two companies beginning immediately. The parties will negotiate a final agreement to include additional terms and conditions.
{iframe}https://www.gsk.com/en-gb/media/press-releases/gsk-to-support-manufacture-of-novavax-covid-19-vaccine/?linkId=100000038322598{/iframe}